Ranolazine for Improving Symptoms of Palpitations (RYPPLE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01495520|
Recruitment Status : Unknown
Verified March 2013 by Francesco Pelliccia, University of Roma La Sapienza.
Recruitment status was: Not yet recruiting
First Posted : December 20, 2011
Last Update Posted : March 7, 2013
|Condition or disease||Intervention/treatment||Phase|
|Ischemic Heart Disease||Drug: Ranolazine Drug: Placebo||Phase 4|
Patients with ischemic heart disease often report multiple symptoms, including angina and palpitations.
Ranolazine is a novel antianginal and antiischemic drug that reduces intracellular sodium and calcium accumulation during ischemia thus limiting ischemic injury. Furthermore, ranolazine has antiarrhythmic effects which are largely a result of the drug's effect on multiple ion channels.
It has previously been shown that treatment with ranolazine can reduce the frequency of supraventricular and ventricular tachycardia in the short term. In a subgroup analysis of the MERLIN-TIMI 36 trial, the continuous ECGs of 6,351 patients were analyzed. The results showed that, in comparison with placebo, treatment with ranolazine resulted in fewer episodes of ventricular tachycardia that lasted 8 beats or longer (5.3% versus 8.3%; P <0.001), and in fewer episodes of supraventricular tachycardia (44.7% versus 55%; P <0.001) and new-onset atrial fibrillation (1.7% versus 2.4%; P=0.08).
It remains unknown, however, whether the favorable effects of ranolazine on symptoms and arrhythmias are maintained over time.
The primary objective of this study is to test the hypothesis that chronic treatment with ranolazine can improve the symptomatic status of patients with ischemic heart disease by reducing the occurrence of palpitations.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Ranolazine for the Treatment of sYmPtoms of PaLpitations in patiEnts With Ischemic Heart Disease - The RYPPLE Trial|
|Study Start Date :||January 2014|
|Estimated Primary Completion Date :||December 2014|
|Estimated Study Completion Date :||December 2016|
Active Comparator: Ranolazine
Patients will receive ranolazine 750 mg bid for 30 days
os, pill, 750 mg, b.i.d., 30 days
Other Name: Ranexa TM, Gilead, US
Placebo Comparator: Placebo
Patients will receive placebo for 30 days
os, pill, b.i.d., 30 days
- Occurrence of symptoms of palpitations [ Time Frame: Up to 30 days ]Occurrence of symptoms of palpitations
- Occurrence of arrhythmia in case of symptoms of palpitations [ Time Frame: Up to 30 days ]Definition of presence, number, type and duration of the arrhythmia in case of the patient-reported symptoms of palpitations
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01495520
|Contact: Francesco Pelliccia, MDemail@example.com|
|Principal Investigator:||Francesco Pelliccia, MD||University Sapienza|